TITLE

Antiretroviral access increased but still room for improvement

PUB. DATE
April 2006
SOURCE
PharmacoEconomics & Outcomes News;4/8/2006, Issue 500, p26
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
According to the latest report issued by the WHO and the Joint United Nations Programme on HIV/AIDS (UNAIDS), the number of patients with HIV infections in low and middle income countries who are receiving antiretroviral (ART) treatments has increased from 400 000 in December 2003 to 1.3 million in December 2005. The report says that the lessons learned in this time should guide future global efforts to provide universal access to such treatment by 2010. Although progress in the scale-up of treatment was lower than anticipated, the report notes that approximately 50 000 patients each month commenced ART therapy during 2005, with the largest efforts observed in sub-Saharan Africa. A total of 18 developing countries met the WHO '3 by 5' target of providing treatment to at least 50% of patients requiring therapy by the end of 2005. Steps to continue and expand ART treatment scale-up are outlined in the report. In addition, UNAIDS estimates that by 2008, approximately $US22 billion per year will be required to fund national programmes for HIV prevention, treatment and care.
ACCESSION #
27697977

 

Related Articles

  • Delayed Progression to Death and to AIDS in a Hong Kong Cohort of Patients with Advanced HIV Type 1 Disease During the Era of Highly Active Antiretroviral Therapy. Ka Hing Wong; Kenny Chi Wai Chan; Shui Shan Lee // Clinical Infectious Diseases;9/15/2004, Vol. 39 Issue 6, p853 

    Background. The magnitude of the impact of highly active antiretroviral therapy (HAART) since its introduction in non-Western countries is not entirely clear. We studied disease progression among adult patients with advanced human immunodeficiency virus type 1 (HIV-1) infection in the pre-HAART...

  • Adherence to Antiretroviral Therapy: How Much Is Enough? Gulick, Roy M. // Clinical Infectious Diseases;10/1/2006, Vol. 43 Issue 7, p942 

    The article presents a study on the efficiency of the antiretroviral therapy. It has been stated that the development of effective antiretroviral therapy in the resulted to significant virologic suppression and immune reconstitution and resulted in dramatic reductions in HIV-related morbidity...

  • Uptake of HIV testing and treatment in an isolated population with access to free and universal healthcare. Gillieatt, Sue J.; Mallal, Simon A.; Gillieatt, S J; Mallal, S A // International Journal of STD & AIDS;May2000, Vol. 11 Issue 5, p303 

    This Western Australian study analysed clinical information from 344 people with AIDS, and experiential data from a sample of 36 people with AIDS to investigate 2 relevant issues: the timing of HIV testing and uptake and experiences of HIV drug treatment. We found that the proportion of people...

  • Ambitious plans to roll out ARVs.  // HIV Australia;Mar-May2004, Vol. 3 Issue 3, p5 

    Reports on the plan to launch antiviral treatment programs at several pilot centres for HIV-positive people across Zimbabwe in 2004. Support of the World Health Organization for the program; Cost of a triple generic drug treatment; Reasons for choosing the pilot sites for the program.

  • Scaling Up Treatment – Why We Can't Wait. Kim, Jim Yong; Gilks, Charlie // New England Journal of Medicine;12/1/2005, Vol. 353 Issue 22, p2392 

    The article presents the author's views on antiretroviral treatment programs for people living with the human immunodeficiency virus (HIV) and AIDS. HIV infection has largely become a manageable, chronic condition in countries rich in resources because of the availability of combination-drug...

  • WHO's use of generic antiretrovirals needs support.  // PharmacoEconomics & Outcomes News;3/12/2005, Issue 473, p2 

    Presents information on a program implemented by the World Health Organization to increase access to antiretrovirals for HIV-infected individuals in developing countries. Efforts to prove the bioequivalence of generic and brand-name antiretrovirals; Criticism of various international agencies...

  • Burden, Determinants, and Pharmacological Management of Hypertension in HIV-Positive Patients and Populations: A Systematic Narrative Review. Anh Nguyen, Kim; Peer, Nasheeta; Mills, Edward J.; Pascal Kengne, Andre // AIDS Reviews;Apr-Jun2015, Vol. 17 Issue 2, p83 

    Hypertension among HIV-positive populations has emerged as a new threat to the health and well being of people living with HIV, particularly among those receiving antiretroviral therapy. We reviewed the global evidence on the burden of disease (including prevalence and incidence), determinants...

  • HIV Drug Resistance Early Warning Indicators in Namibia with Updated World Health Organization Guidance. Jonas, Anna; Sumbi, Victor; Mwinga, Samson; DeKlerk, Michael; Tjituka, Francina; Penney, Scott; Jordan, Michael R.; Desta, Tiruneh; Tang, Alice M.; Hong, Steven Y. // PLoS ONE;Jul2014, Vol. 9 Issue 7, p1 

    Background: In response to concerns about the emergence of HIV drug resistance (HIVDR), the World Health Organization (WHO) has developed a comprehensive set of early warning indicators (EWIs) to monitor HIV drug resistance and good programme practice at antiretroviral therapy (ART) sites....

  • HIV guideline changes could slow virus spread.  // New Scientist;12/5/2009, Vol. 204 Issue 2737, p7 

    The article reports on the advice issued by the World Health Organization (WHO) to administer antiretroviral therapy (ART) to people with human immunodeficiency virus (HIV) earlier in the infection cycle. WHO suggests that ART be started when the levels of CD4 immune cells decreased below 200...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics